Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03461952
Title Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST